ArticleLancet regional health. Americas2026
Clinical and molecular characterization of a large Brazilian lung cancer cohort: a real-world observational study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TP53 p.Arg337His in Brazilian lung cancer: when tumour profiling should trigger germline evaluation.Lancet regional health. Americas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Driver alterations influence lung cancer management and vary among ethnicities. Patients from Latin America remain underrepresented in genomic studies. We characterized the molecular and ancestry profiles of Brazilian patients with lung cancer using real-world data and evaluated associations with clinicopathological features. Methods: We retrospectively analyzed 1131 patients with lung cancer from a referral center, using DNA/RNA-based Next-generation Sequencing (NGS), immunohistochemistry, and ancestry-informative markers to assess molecular profiles and associate them with clinical features. Findings: Oncogenic alterations were detected in 988 (88%) of patients, mainly at Interpretation: Most Brazilian patients with lung cancer harbor actionable genomic alterations. Funding: Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer-15th zone, Campinas, Brazil), PRONON-PRONON/MS (Abordagens móveis e de tecnologia para prevenção primária e secundária de câncer-NUP: 25000.015000/2019-53), and Barretos Cancer Hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.